Navkar Corporation Ltd
Q1 FY22 Earnings Call Analysis
Transport Services
fundraise: Yescapex: Yesrevenue: Category 3margin: Category 1orderbook: No information
💰fundraise
Any current/future new fundraising through debt or equity?
- The company has a total CAPEX plan of Rs. 135 crores for the new ICD, with around Rs. 100 crores tied up via a loan from Canara Bank; the rest is funded through cash flow.
- For train replacements, an additional Rs. 150-200 crores CAPEX is planned this year, partially funded by loans.
- Debt is expected to increase by approximately Rs. 50 crores this year due to these CAPEX and train replacements.
- There is no explicit mention of new equity fundraising in the discussed sections.
- The company aims to repay loans ahead of schedule once cash flows improve, based on past history of early repayments.
- No direct comment on future equity issuance; focus is on utilizing loans and cash flows for expansion and repayments.
🏗️capex
Any current/future capex/capital investment/strategic investment?
- Ongoing CAPEX of ₹135 crores for new ICD facility at Morbi with ~40% completion (Page 5, 9, 12).
- Target to make ICD Morbi operational by Q3 FY 22-23 (around September-October 2022) (Page 5, 9,12).
- Additional ₹100 crore tied up with Canara Bank for Morbi project; remaining funded via cash flow (Page 9).
- Replacement of 12 leased trains with owned trains planned, improving operational efficiency and reducing costs (Page 8,14).
- Total capacity post-Morbi expected to be over 1 million TEUs; phased capacity addition and incremental revenue of ₹50 crores from Morbi anticipated in first year (Page 9, 12).
- Focus on strategic growth via Morbi, Vapi ICD facilities, and cross-selling to improve margins up to ~30% over 2-3 years (Page 9, 12, 14).
- Further CAPEX plans depend on business growth and government policies like Gati Shakti and Dedicated Freight Corridor (Page 8,11,14).
📊revenue
Future growth expectations in sales/revenue/volumes?
- Current utilization of 50% with a target to improve utilization by at least 10% annually.
- Capacity expected to increase to around 1 million TEUs after commissioning Morbi facility.
- Morbi ICD targeted to start operations by Q3 FY 22-23, with first-year revenue expected around Rs. 50 crores.
- Peak revenue from Morbi projected at Rs. 400 crores within 3-4 years.
- Capacity utilization growth driven by domestic, EXIM, and cross-selling business across Mumbai, Vapi, and Morbi locations.
- Anticipated gradual increase in volumes aligned with government policies and easing container availability.
- Replacement of lease trains with owned trains expected to improve operational efficiency and margins.
- Overall target to grow EBITDA margins by approximately 20% considering new initiatives like Gati Shakti and Morbi operations.
📈margin
Future growth expectations in earnings/operating earnings/profits/EPS?
- The company targets around 10% annual growth in capacity utilization from current ~50%.
- After Morbi ICD becomes operational (targeting Q3 FY22-23), revenue is expected to increase by ₹50 crores in the first year.
- Peak revenue from Morbi is projected at around ₹400 crores within 3-4 years.
- Operating margin (EBITDA) targeted to improve from current ~24% to around 30% over the next 2-3 years.
- Ownership of trains (replacing leased) expected to save approximately ₹2.5 crores annually and improve operational efficiency.
- Benefits from government schemes (Gati Shakti, DFCC) expected to enhance profitability by 20% in a couple of years.
- Diesel price hikes partly passed to customers; no major margin impact anticipated going forward.
- Overall steady and gradual earnings growth is expected, with no extraordinary growth forecast but stable improvements.
📋orderbook
Current/ Expected Orderbook/ Pending Orders?
- The transcript does not provide explicit details on the current or expected order book or pending orders in numeric terms.
- However, the company is actively targeting new customers daily and expanding its operations across multiple facilities, including Mumbai, Vapi, and the upcoming Morbi ICD.
- They have engaged with over 2,000 clients in Morbi across tile, paper, and chemical industries.
- The company aims to grow its capacity utilization gradually by at least 10% annually.
- Revenue targets include approximately Rs 50 crore additional revenue from the new Morbi ICD in the first year and a peak revenue of around Rs 400 crore over the next 3-4 years.
- The management expects capacity utilization to improve post Morbi operations and the operationalization of schemes like Gati Shakti and DFCC, which will further boost business and margins.
